ABVC
ABVC BioPharma, Inc. [ABVC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ABVC Stock Summary
Top 10 Correlated Stocks
ABVC
In the News
ABVC Financial details
Company Rating
Sell
Market Cap
11.51M
Income
-8.77M
Revenue
152.43K
Book val./share
1.11
Cash/share
0.1
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.63
Forward P/E
-
PEG
0.1
P/S
16.55
P/B
0.7
P/C
10.2
P/FCF
-2.89
Quick Ratio
0.32
Current Ratio
0.46
Debt / Equity
0.28
LT Debt / Equity
0.05
-
-
EPS (TTM)
-1.91
EPS next Y
-
EPS next Q
-
EPS this Y
-52.82%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.55%
Revenue last 5Y
-26.31%
Revenue Q/Q
-86.37%
EPS Q/Q
-52.44%
-
-
-
-
SMA20
-3.36%
SMA50
-18.44%
SMA100
-20.69%
Inst Own
1.78%
Inst Trans
0.91%
ROA
-61%
ROE
-301%
ROC
-0.84%
Gross Margin
42%
Oper. Margin
-1270%
Profit Margin
-1374%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.674-9.6
52W High
-
52W Low
-
RSI
35.61
Rel Volume
2.42
Avg Volume
732.5K
Volume
1.77M
Perf Week
-18.4%
Perf Month
-15.7%
Perf Quarter
14.61%
Perf Half Y
8.51%
-
-
-
-
Beta
0.769
-
-
Volatility
0.05%, 0.09%
Prev Close
-8.93%
Price
1.02
Change
-3.77%
ABVC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.4 | 0.25 | 0.14 | 0.31 | 0.04 | |
| Net income per share | -2.25 | -5.37 | -4.8 | -5.15 | -2.43 | |
| Operating cash flow per share | -1.79 | -2.31 | -3.03 | -2.34 | -0.94 | |
| Free cash flow per share | -1.79 | -2.31 | -3.04 | -2.37 | -0.94 | |
| Cash per share | 0.08 | 2.17 | 2.37 | 0.05 | 0.18 | |
| Book value per share | -0.09 | 1.74 | 3.53 | 0.98 | 2.04 | |
| Tangible book value per share | -0.07 | 1.35 | 3.54 | 1.14 | 1.98 | |
| Share holders equity per share | -0.09 | 1.74 | 3.53 | 0.98 | 2.04 | |
| Interest debt per share | 2.89 | 3.49 | 1.33 | 1.06 | 1.14 | |
| Market cap | 76.47M | 100.55M | 84.93M | 19.79M | 5.03M | |
| Enterprise value | 80.9M | 102.76M | 82.21M | 22.76M | 6.76M | |
| P/E ratio | -19.44 | -9.49 | -7.06 | -1.21 | -0.48 | |
| Price to sales ratio | 108.97 | 208.16 | 238.71 | 20.41 | 32.99 | |
| POCF ratio | -24.4 | -22.03 | -11.18 | -2.67 | -1.24 | |
| PFCF ratio | -24.4 | -22.03 | -11.15 | -2.63 | -1.23 | |
| P/B Ratio | -506.54 | 29.24 | 9.6 | 6.39 | 0.57 | |
| PTB ratio | -506.54 | 29.24 | 9.6 | 6.39 | 0.57 | |
| EV to sales | 115.29 | 212.73 | 231.07 | 23.47 | 44.37 | |
| Enterprise value over EBITDA | -24.79 | -12.53 | -7.39 | -1.54 | -0.83 | |
| EV to operating cash flow | -25.81 | -22.52 | -10.82 | -3.08 | -1.66 | |
| EV to free cash flow | -25.81 | -22.52 | -10.8 | -3.03 | -1.66 | |
| Earnings yield | -0.05 | -0.11 | -0.14 | -0.82 | -2.09 | |
| Free cash flow yield | -0.04 | -0.05 | -0.09 | -0.38 | -0.81 | |
| Debt to equity | -30.33 | 1.89 | 0.35 | 0.99 | 0.28 | |
| Debt to assets | 0.66 | 0.56 | 0.23 | 0.31 | 0.16 | |
| Net debt to EBITDA | -1.36 | -0.27 | 0.24 | -0.2 | -0.21 | |
| Current ratio | 0.13 | 1.27 | 2.61 | 0.51 | 0.28 | |
| Interest coverage | -7.18 | -21 | -49.93 | -51.42 | -3.3 | |
| Income quality | 0.8 | 0.43 | 0.63 | 0.45 | 0.39 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 4.41 | 17.43 | 31.07 | 13.51 | 45.95 | |
| Research and developement to revenue | 1.49 | 1.14 | 2.82 | 2.78 | 6.97 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.02 | 0.01 | |
| Capex to revenue | 0 | 0 | -0.05 | -0.12 | -0.14 | |
| Capex to depreciation | 0 | 0 | -1.46 | -5.03 | -0.74 | |
| Stock based compensation to revenue | 0.03 | 8.59 | 14.92 | 7.26 | 10.73 | |
| Graham number | 2.09 | 14.52 | 19.53 | 10.65 | 10.55 | |
| ROIC | -0.68 | -0.71 | -0.91 | -2.17 | -0.72 | |
| Return on tangible assets | -0.57 | -0.91 | -0.88 | -1.66 | -0.7 | |
| Graham Net | -3.81 | -2.2 | 0.96 | -1.39 | -1.15 | |
| Working capital | -5.94M | 1.33M | 5.93M | -2.83M | -4.28M | |
| Tangible asset value | -124.82K | 2.66M | 8.87M | 3.62M | 8.58M | |
| Net current asset value | -6.17M | -2.77M | 4.8M | -3.25M | -4.7M | |
| Invested capital | -30.33 | 1.89 | 0.35 | 0.99 | 0.28 | |
| Average receivables | 340.26K | 819.96K | 1.36M | 1.54M | 1.06M | |
| Average payables | 12K | 23.52K | 11.52K | 0 | 56.47K | |
| Average inventory | -238.48K | -658.33K | -406.86K | 666.22K | 653.23K | |
| Days sales outstanding | 333.17 | 755.17 | 1.76K | 515.44 | 1.82K | |
| Days payables outstanding | 434.93 | 449.4 | 0 | 0 | 124.71 | |
| Days of inventory on hand | -8.65K | -16.38K | 1.86K | 1.66K | 0 | |
| Receivables turnover | 1.1 | 0.48 | 0.21 | 0.71 | 0.2 | |
| Payables turnover | 0.84 | 0.81 | 0 | 0 | 2.93 | |
| Inventory turnover | -0.04 | -0.02 | 0.2 | 0.22 | 0 | |
| ROE | 26.05 | -3.08 | -1.36 | -5.26 | -1.19 | |
| Capex per share | 0 | 0 | -0.01 | -0.04 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.18 | 0.04 | 0 | 0 | 0 | |
| Net income per share | -1.38 | -0.02 | -0.68 | -0.82 | -0.39 | |
| Operating cash flow per share | -0.14 | -0.45 | -0.27 | -0.34 | -0.06 | |
| Free cash flow per share | -0.14 | -0.45 | -0.27 | -0.34 | -0.06 | |
| Cash per share | 0.05 | 0.37 | 0.05 | 0.14 | 0.1 | |
| Book value per share | 0.95 | 0.51 | -0.11 | 2.24 | 1.11 | |
| Tangible book value per share | 0.99 | 0.52 | -0.11 | 2.23 | 1.08 | |
| Share holders equity per share | 0.95 | 0.51 | -0.11 | 2.24 | 1.11 | |
| Interest debt per share | 0.98 | 1.59 | 1.6 | 1.14 | 0.45 | |
| Market cap | 20.36M | 21.17M | 17.21M | 4.22M | 9.21M | |
| Enterprise value | 23.33M | 25.24M | 22.29M | 7.12M | 10.95M | |
| P/E ratio | -1.13 | -71.97 | -1.9 | -0.32 | -0.74 | |
| Price to sales ratio | 34.57 | 165.03 | 2.82K | 265.52 | 4.25K | |
| POCF ratio | -44.17 | -14.13 | -19.12 | -3.1 | -19.94 | |
| PFCF ratio | -44.16 | -14.13 | -19.12 | -3.06 | -20.9 | |
| P/B Ratio | 6.57 | 12.67 | -45.36 | 0.46 | 1.04 | |
| PTB ratio | 6.57 | 12.67 | -45.36 | 0.46 | 1.04 | |
| EV to sales | 39.62 | 196.78 | 3.65K | 448.49 | 5.06K | |
| Enterprise value over EBITDA | -7.77 | -13.85 | -10.65 | -3.36 | -5.6 | |
| EV to operating cash flow | -50.61 | -16.85 | -24.77 | -5.24 | -23.69 | |
| EV to free cash flow | -50.6 | -16.85 | -24.77 | -5.16 | -24.83 | |
| Earnings yield | -0.22 | 0 | -0.13 | -0.79 | -0.34 | |
| Free cash flow yield | -0.02 | -0.07 | -0.05 | -0.33 | -0.05 | |
| Debt to equity | 0.99 | 3.12 | -13.66 | 0.37 | 0.28 | |
| Debt to assets | 0.31 | 0.49 | 0.56 | 0.21 | 0.16 | |
| Net debt to EBITDA | -0.99 | -2.24 | -2.43 | -1.37 | -0.89 | |
| Current ratio | 0.51 | 0.69 | 0.37 | 0.46 | 0.28 | |
| Interest coverage | -23.3 | -33.64 | -19.12 | -1.77 | -1.78 | |
| Income quality | 0.1 | 0.79 | 0.39 | 0.4 | 0.15 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.33 | 12.78 | 263.96 | 125.9 | 809.42 | |
| Research and developement to revenue | 2.54 | 2.61 | 84.21 | 8.9 | 33.34 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.02 | -0.05 | |
| Capex to revenue | 0 | 0 | 0 | -1.33 | 9.79 | |
| Capex to depreciation | -0.01 | 0 | 0 | -2.84 | 2.8 | |
| Stock based compensation to revenue | 3.21 | 2.86 | 36.95 | 51.48 | 104.27 | |
| Graham number | 5.44 | 0.5 | 1.33 | 6.43 | 3.13 | |
| ROIC | -0.54 | -0.01 | -0.39 | -0.16 | -0.18 | |
| Return on tangible assets | -0.46 | -0.01 | -0.24 | -0.2 | -0.21 | |
| Graham Net | -1.47 | -2.25 | -2.7 | -1.43 | -0.63 | |
| Working capital | -2.83M | -1.59M | -3.64M | -2.87M | -4.28M | |
| Tangible asset value | 3.24M | 1.73M | -367.01K | 9.06M | 8.58M | |
| Net current asset value | -3.63M | -5.52M | -7.56M | -5.04M | -4.7M | |
| Invested capital | 0.99 | 3.12 | -13.66 | 0.37 | 0.28 | |
| Average receivables | 958.58K | 1.32M | 1.21M | 1.16M | 960.26K | |
| Average payables | 0 | 0 | -39.75K | -79.5K | 16.72K | |
| Average inventory | 663.48K | 45.13K | -899.77K | 18.76K | 310.43K | |
| Days sales outstanding | 209.26 | 885.68 | 17.12K | 6.58K | 31.58K | |
| Days payables outstanding | 0 | 0 | -98.04 | -241.61 | 69.25 | |
| Days of inventory on hand | 443.02 | -1.82K | -719.38 | 1.89K | 0 | |
| Receivables turnover | 0.43 | 0.1 | 0.01 | 0.01 | 0 | |
| Payables turnover | 0 | 0 | -0.92 | -0.37 | 1.3 | |
| Inventory turnover | 0.2 | -0.05 | -0.13 | 0.05 | 0 | |
| ROE | -1.45 | -0.04 | 5.97 | -0.36 | -0.35 | |
| Capex per share | 0 | 0 | 0 | -0.01 | 0 |
ABVC Frequently Asked Questions
What is ABVC BioPharma, Inc. stock symbol ?
ABVC BioPharma, Inc. is a US stock , located in Fremont of Ca and trading under the symbol ABVC
What is ABVC BioPharma, Inc. stock quote today ?
ABVC BioPharma, Inc. stock price is $1.02 today.
Is ABVC BioPharma, Inc. stock public?
Yes, ABVC BioPharma, Inc. is a publicly traded company.
Company Profile
- Volume Average 732.5K
- Market Capitalization 11.51M
- Employee 16
- CEO Dr. Uttam Yashwant Patil Ph.D.
- Headquarters Fremont,CA,US
- IPO Date 2004-11-10
-
Website
https://www.abvcpharma.com 
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
